Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (261-270 of 760) with videos related to

Pageof 76
Sort By:
Journal of Thrombosis and Thrombolysis|August 18, 2020
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activationMaria Luisa Guarino, Isabella Massimi, Laura Alemanno, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 19, 2021
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trialsMattia Galli, Davide Capodanno, Stefano Benenati, et al.
Cardiovascular Drugs and Therapy|June 17, 2022
Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H<sub>2</sub> Receptor BlockersMuzamil Khawaja, Janki Thakker, Riyad Kherallah, et al.
Clinical Pharmacokinetics|June 14, 2023
Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112Luis Ortega-Paz, Salvatore Giordano, Davide Capodanno, et al.
International Journal of Cardiology|October 11, 2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixabanFrancesco Pelliccia, Fabiana Rollini, Giuseppe Marazzi, et al.
American Journal of Therapeutics|October 3, 2009
Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitroVictor L Serebruany, Mohamed El Mouelhi, Hans-Jürgen Pfannkuche, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 18, 2008
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologistsDominick J Angiolillo, Siva Suryadevara, Piera Capranzano, et al.
Journal of Thrombosis and Thrombolysis|October 12, 2014
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery diseaseMatthew J Price, Leonardo Clavijo, Dominick J Angiolillo, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 16, 2024
Switching from cangrelor to oral P2Y<sub>12</sub> inhibitors: a focused review on drug-drug interactionsGiovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, et al.
Journal of Thrombosis and Thrombolysis|September 6, 2024
Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospitalMattia Galli, Sergio Terracina, Eleonora Schiera, et al.
Pageof 76

Showing results (261-270 of 760) with videos related to

Sort By:
Pageof 76
Journal of Thrombosis and Thrombolysis|August 18, 2020
MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activationMaria Luisa Guarino, Isabella Massimi, Laura Alemanno, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 19, 2021
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trialsMattia Galli, Davide Capodanno, Stefano Benenati, et al.
Cardiovascular Drugs and Therapy|June 17, 2022
Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H<sub>2</sub> Receptor BlockersMuzamil Khawaja, Janki Thakker, Riyad Kherallah, et al.
Clinical Pharmacokinetics|June 14, 2023
Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112Luis Ortega-Paz, Salvatore Giordano, Davide Capodanno, et al.
International Journal of Cardiology|October 11, 2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixabanFrancesco Pelliccia, Fabiana Rollini, Giuseppe Marazzi, et al.
American Journal of Therapeutics|October 3, 2009
Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitroVictor L Serebruany, Mohamed El Mouelhi, Hans-Jürgen Pfannkuche, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 18, 2008
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologistsDominick J Angiolillo, Siva Suryadevara, Piera Capranzano, et al.
Journal of Thrombosis and Thrombolysis|October 12, 2014
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery diseaseMatthew J Price, Leonardo Clavijo, Dominick J Angiolillo, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 16, 2024
Switching from cangrelor to oral P2Y<sub>12</sub> inhibitors: a focused review on drug-drug interactionsGiovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, et al.
Journal of Thrombosis and Thrombolysis|September 6, 2024
Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospitalMattia Galli, Sergio Terracina, Eleonora Schiera, et al.
Pageof 76